Latest News


Each news article below shows only part of the news story. To view the full story, click on Read More below the story. 

  • November 01, 2018 8:13 AM | Anonymous
    November 1, 2018, AAPA  


    Here's some good news for you — the lowest rates for the only national PA conference start now! Join thousands of PAs in Denver from May 18-22 for CME, networking, social events, and more. Register now to save. Plus, book your hotel room in the official AAPA hotel block and knock another $200 OFF your registration rate. 

    Don't forget - APAOG is planning a member meeting at AAPA 2019! Watch for more details on when and where to join us! 

    Register today and save!

  • October 31, 2018 7:57 AM | Anonymous

    October 31, 2018, News Medical  

    Ultrasound is one of the three main technologies used in medical imaging. It is more compact and affordable than nuclear magnetic resonance imaging (MRI) techniques, and safer than X-rays. But the images it produces are often difficult to interpret. A research team has developed a new method based on the speed of sound. 

    Read more.

  • October 26, 2018 11:20 AM | Anonymous

    October 26, 2018, Cancer Research UK via Medical Xpress  

    A drug could help slow the progression of some advanced ovarian cancers and extend the time that patients show no signs of disease, according to new clinical trial results. The study, published in the New England Journal of Medicine, found that the drug olaparib (Lynparza) could delay the return of advanced ovarian cancer in some woman whose cancer cells carry a faulty BRCA gene, or stopped the disease from getting worse.

    Read more.

  • October 25, 2018 1:25 PM | Anonymous

    October 25, 2018, Cure Today 

    The anti-PD-1 monoclonal antibody TSR-042 appeared to be safe and effective in the treatment of patients with microsatellite-high (MSI-H) endometrial cancer, according to preliminary results presented at the European Society for Medical Oncology (ESMO)'s 2018 Congress.  

    Read more.

  • October 25, 2018 1:22 PM | Anonymous

    October 25, 2018, Medscape  

    The so-called liquid biopsy holds great promise for detecting a variety of cancers more accurately, guiding individualized therapy, and improving monitoring during treatment. New data suggest that testing for plasma circulating tumor human papillomavirus DNA (ctHPVDNA) can be an effective method of surveillance for patients with p16-positive oropharyngeal squamous cell carcinoma (OPSCC). c

    Read more.

  • October 23, 2018 10:37 AM | Anonymous

    October 22, 2018, European Society for Medical Oncology via Medical Xpress  

    Targeting a common mutation in patients with hormone receptor positive (HR+) HER2 negative (HER2-) advanced breast cancer with the alpha-specific phosphatidylinositol-3-kinase (PI3K) inhibitor alpelisib significantly improves progression-free survival, according to late-breaking results reported at ESMO 2018.  

    Read more.

  • October 23, 2018 10:34 AM | Anonymous

    October 22, 2018, Medscape   

    A first-of-its kind phase 3 study found that patients with advanced ovarian cancer who carry a BRCA mutation have a marked increase in progression-free survival (PFS) if they are given maintenance therapy with the poly(ADP)-ribose polymerase (PARP) inhibitor olaparib (Lynparza, AstraZeneca) following successful first-line chemotherapy. 

    Read more.

  • October 18, 2018 1:35 PM | Anonymous

    October 18,2018, Via CARDEA Services | Training, Organizational Development and Research 


    Independent Study:
    HIV Care and Sexual Health Assessment for
    American Indian and Alaska Native Patients

    Register now for the free online continuing education opportunity!

    This course will help prepare you to provide optimal HIV prevention, screening and treatment in any primary care setting. You will learn practical tips for performing a brief sexual health assessment and how to provide HIV and sexual health services in a culturally sensitive manner to people of all genders and sexual orientations. Cardea designed this four-module online learning course in partnership with the Urban Indian Health Institute, a division of the Seattle Indian Health Board (SIHB/UIHI). Each of the modules includes a written transcript of the audio/narration that is approximately 30 minutes in length.


    Who Should Attend

    This course is designed for staff who provide medical care to patients in a variety of clinical settings. While created specifically for staff who provide care for American Indian and Alaska Native patients, many of the core concepts, video-taped scenarios, and approaches are also relevant to health care providers who serve diverse patient populations. Physicians, physician assistants, nurse practitioners, nurses, medical assistants and other staff involved in patient care will benefit from this new course on conducting gender-inclusive sexual health assessment and providing HIV care.


    Registration & Fees

    This course is FREE OF CHARGE.     

    Click here to register


    Continuing Medical Education Information 

    Continuing Nursing Education (CNE)

    Cardea Services is an approved provider of continuing nursing education by Montana Nurses Association, an accredited approver with distinction by the American Nurses Credentialing Center's Commission on Accreditation.

    HIV Care and Sexual Health Assessment for American Indian and Alaska Native Patients: 3 contact hours will be awarded. This activity expires on September 30, 2020.

    Continuing Medical Education (CME)

    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Institute for Medical Quality/California Medical Association (IMQ/CMA) through the joint providership of Cardea and the Urban Indian Health Institute, a division of the Seattle Indian Health Board. Cardea is accredited by the IMQ/CMA to provide continuing medical education for physicians.

    Cardea designates this internet activity enduring material for a maximum of 3 AMA PRA Category 1 Credit(s)™.Physicians should claim credit commensurate with the extent of their participation in the activity.

    Successful completion of this continuing education activity includes the following:

    • Completing the entire CE activity
    • Passing the post-test with a score of 80% or greater
    • Completing the online evaluation
    • Submitting an online CE Request

    Expiration date: This activity was originally released on October 1, 2018 and is available for continuing education credit until September 30, 2020.

    Funding

    Cardea Services developed this independent study in partnership with the Urban Indian Health Institute a division of the Seattle Indian Health Board.

    Questions?

    Contact our Oakland office at 510.835.3700 or oakland@cardeaservices.org


  • October 18, 2018 9:22 AM | Anonymous

    October 18, 2018, The Pharma Letter 

    The U.S. Food and Drug Administration approved Talzenna (talazoparib), a poly (ADP-ribose) polymerase (PARP) inhibitor, for patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), HER2‑negative locally advanced or metastatic breast cancer. Patients must be selected for therapy based on an FDA-approved companion diagnostic for talazoparib. 

    Read more.

  • October 18, 2018 9:20 AM | Anonymous

    October 18, 2018, HealthDay News via Medical Xpress

    American women are having fewer children, and they're having them later in life, a new government report shows. "Overall, we saw continuing decreasing trends in total fertility," said report author Danielle Ely, a health statistician at the National Center for Health Statistics (NCHS), which is part of the U.S. Centers for Disease Control and Prevention.  

    Read more.

Powered by Wild Apricot Membership Software